INTRODUCTION
Diabetes mellitus (DM) is a specific disease, on the background of which there has been an increase in comorbid pathologies in the recent years. Diabetes accounts for disruption of all types of substances of metabolism and affects all organs and systems of the body including the digestive system (esophagus, stomach, intestine, liver and pancreas) [1]. Of particular interest is the study of the combined course of chronic pancreatitis (CP) and diabetes (DM) simultaneously affecting two different functions of the same organ [2, 3].

Chronic pancreatitis (CP) is one of the most complex polyethiological and polymorbid diseases [4]. The summation and potentiation of adverse effects of risk factors and the action of etiological factor of CP contribute to the growth of its incidence rate and progressive course, with exocrine insufficiency of the pancreas, development of mal-digestion, malabsorption and trophological insufficiency in patients with impaired metabolism of all substances [5, 6].

Failure of the autonomic nervous system, i.e. diabetic autonomic neuropathy (DAN) is a serious and common complication that is observed in 16.8–54.0% of DM patients. However, DAN remains among the least studied complications due to its long asymptomatic course. It is often diagnosed late, and therefore difficult to treat due insufficiently developed methods of early diagnosis and treatment. Diabetic autonomic gastrointestinal neuropathy, with its characteristic gastroparesis, enteropathy and cholecystoparesis, is one of the main causes of labile course of the disease. It also increases the risk of gallstone disease 2-5 times in patients with DM compared to the general population [7].

Given the above facts, detecting DAN in patients with type 2 diabetes, especially when combined with CP, is of important diagnostic value for these patients. In this process, the study of the functional state of the upper abdominal organs, namely the biliary system, gastroesophageal area (with the focus on the gastric acid secretion) can largely serve as one of the main elements for early diagnosis of digestive changes that can aggravate the clinical course of the existing pathology.

THE AIM
Aim of the research is to determine the peculiarities of changes in the gastric acid secretion against the background of diabetic autonomic neuropathy and autonomic dysfunction in patients with CP and type 2 diabetes.
Yelyzaveta S. Sirchak et al.

The difference between the indicators in patients of Group I and Group II is statistically significant: $p < 0.05$. The difference between the indicators in patients of Group III and patients of Groups I and II is statistically significant: $+ - p < 0.05; ++ - p < 0.01$; the difference between the indicators in patients of Group I and Group II is statistically significant: $^\wedge - p < 0.05$.

**MATERIALS AND METHODS**

64 patients with CP and type 2 diabetes were examined and divided into the first group of the patients (35 male (54.7%) and 29 female (45.3%) of an average age of 48.9 ± 6.3). Group II consisted of 40 patients with type 2 diabetes (22 men (55.0%) and 18 women (45.0%) at an average age of 48.9 ± 6.3 years); and Group III of the patients consisted of 34 patients with CP (21 male (61.8%) and 13 female (38.2%) of an average age of 46.7 ± 4.2 years). All examined patients were either hospitalized in the Endocrinology and Gastroenterology Departments of Municipal Non Profit Enterprise “Transcarpathian Regional Clinical Hospital Named Afer Andrii Novak” of Transcarpathian Regional Council or were on outpatient observation by the district family doctors at the place of their residence.

The control group included 20 healthy individuals (11 male (55.0%) and 9 female (45.0%) of an average age of 45.2 ± 5.1). All studies were performed with the consent of the patients, and their methodology was in line with the Helsinki Declaration of Human Rights of 1975 and its revision of 1983, the Council of Europe Convention on Human Rights and Biomedicine and the current legislation of Ukraine.

All patients were examined using general clinical, anthropometric, instrumental and laboratory research methods. All patients also underwent ultrasound examination of the abdominal cavity by conventional methods. Standard general and biochemical studies of blood serum were conducted with an emphasis on carbohydrate metabolism (glucose, glycated hemoglobin, insulin, C-peptide, proinsulin and glucose tolerance test).

The diagnosis of CP was established in accordance with the Marseille-Roman criteria (1989) with the addition of Ya.S. Zimmerman (1995) and clarifications of ICD-10. A coprological study was performed, serum amylase and fecal elastase-1 levels were determined, and $^{13}C$-mixed triglyceride ($^{13}C$-CTDT) and $^{13}C$-amylase respiratory tests ($^{13}C$-ADT) were used to study the exocrine function of the pancreas.

Medical care was provided to the examined patients with diabetes according to the clinical protocols of the Ministry of Health of Ukraine and local protocols. The diagnosis of type 2 diabetes was established in accordance with the recommendations of the IDF (2005), as well as taking into account the criteria of a unified clinical protocol (The Ministry of Health of Ukraine Order of 21.12.2012 № 1118) [8, 9]. The severity of type 2 diabetes was assessed by the level of HbA1c (Normal: up to 6.0%).

To diagnose diabetic autonomic neuropathy (DAN), all patients underwent a cardiac rhythmogram (with Polar Pro heart rate monitor), during which heart rate was measured using a sensor that was applied to the chest over the projection of the apex of the heart, with the recording of heart contractions. Assessment of cardiovascular diabetic neuropathy was performed by standard Ewing tests (assessment of changes in heart rate (HR) with slow deep breathing (6 breaths per minute)); Shellong test (orthostatic test) and 30:15 test, as these tests are proposed as a standard for the diagnosis of DAN (San-Antonio, 1998).

Detection of autonomic dysfunction (AD) was performed using the O.M. Wayne's questionnaire (1998). The score above 15 indicated AD. Also, the Kérdö's Vegetative Index was calculated (KVI) on the basis of hemodynamic parameters (HR, blood pressure):

$$KVI = \left(1 - \text{diastolic blood pressure (DBP) / pulse}\right) \times 100.$$

At full vegetative balance (euytonia) the index is in the range from -10 to +10. With the predominance of sympathetic influences (sypathicotonia) the value of KVI will be higher than +10, and with the predominance of parasympathetic influences (vagotonia) the value of KVI will be lower than -10.

To study the gastric acid secretion of the stomach, patients underwent intragastric express pH-metry, using a computer system according to the method of Prof. V.N. Chernobroy. The study was conducted in the morning (7.00-9.00 hours). To accurately assess basal acidity 24 hours before the study, the use of any antacids was excluded.

Each patient was administered a pH microprobe through the mouth, the beginning of the pH measurement was carried out at the level of the transition of the esophagus into the stomach, which in most patients was 40 cm at the depth of the probe (from incisors). For the entire length of the stomach (from the cardia to the pylorus), the pH was measured every 1 cm, each time for 15-20 seconds. The technique of basal topographic pH-metry requires both the introduction and removal of the pH microprobe along the entire length of the stomach. There was a time interval of 5-10 minutes between the input and output of the probe. To evaluate the results, we took into account the functional pH interval/range (FI pH) from 0 to 5 (in the direction of increasing gastric acidity):
peculiarities of determining the gastric acid secretion and diabetic autonomic neuropathy. ...
of Group III (patients with CP) indicators of the functional state of the ANS indicates a slight predominance of the sympathetic division.

Analysis of gastric acid secretion indicates that no patients of Group III had normal acidity. Normal acidity is more often found in the second group of subjects (with type 2 diabetes). Both in patients with CP and type 2 diabetes, and in isolation with CP, moderate hyperacidity was more often determined (in 42.2% of patients of I and 45.0% of patients of Group III). At the same time, in patients of Group I moderate hyperacidity was mostly total and subtotal, while in patients of Group III – more often selective and absolute. Severe hyperacidity is also more common in CP and in patients with a combination of CP and type 2 diabetes. In patients of Group I, pronounced hyperacidity was mostly subtotal, total and absolute, and in patients of Group III – total, absolute and selective hyperacidity were more often diagnosed. Patients of Group II (patients with type 2 diabetes) are more likely to have normal acidity and moderate hyperacidity.

It should be noted that in characterizing the clinical manifestations of gastric dyspepsia, such signs as heartburn, acid regurgitation and epigastric pain occurred only among the examined Group III. In patients of the Groups I and II signs of biliary dyspepsia (bitter taste in the mouth, belching with bitter aftertaste), and also heaviness mainly in the right upper quadrant came to the fore.

**DISCUSSION**

Diabetic autonomic neuropathy (DAN) is a serious and common complication of diabetes, often overlooked and misdiagnosed. Diabetic autonomic neuropathy may involve the cardiovascular, genitourinary, and the neuroendocrine systems as well as the upper and lower gastrointestinal (GI) tract. Abnormalities of GI function in diabetics are thought to be related, at least in part, to autonomic neuropathy [10].

Our studies indicate that in patients with type 2 diabetes, especially in combination with CP, there is an impairment of gastric acid secretion, which is mainly manifested by hyperacidity. However, in these patients symptoms of gastrointestinal lesions are not pronounced against the background of DAN and autonomic disorders, and this in many respects complicates timely diagnosis and adequate pathogenetically substantiated treatment.

The professional literature discusses the violation of the acid-forming function of the stomach, mainly in the defeat of the upper gastrointestinal tract and in its combination with other pathological conditions. Skubytska LD, Severynovska OV (2015) indicate the dependence of

**Table III. Characteristics of gastric acidity in the examined patients**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Group 1(CP+T2DM) (n=64)</th>
<th>Group 2 (T2DM) (n=34)</th>
<th>Group 2 (CP) (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate hypoacidity:</td>
<td>4.7 % *</td>
<td>11.7 %</td>
<td>-</td>
</tr>
<tr>
<td>selective</td>
<td>33.3 % **</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>absolute</td>
<td>66.7 % *</td>
<td>50.0 %</td>
<td>-</td>
</tr>
<tr>
<td>subtotal</td>
<td>-</td>
<td>50.0 % **</td>
<td>-</td>
</tr>
<tr>
<td>Normal acidity:</td>
<td>21.9 % *</td>
<td>35.3 %</td>
<td>25.0 %</td>
</tr>
<tr>
<td>selective</td>
<td>21.4 %</td>
<td>41.7 %</td>
<td>10.0 %</td>
</tr>
<tr>
<td>absolute</td>
<td>35.7 % +</td>
<td>33.3 %</td>
<td>50.0 %</td>
</tr>
<tr>
<td>subtotal</td>
<td>42.9 %</td>
<td>25.0 %</td>
<td>40.0 %</td>
</tr>
<tr>
<td>Moderate hyperacidity:</td>
<td>42.2 %</td>
<td>32.4 %</td>
<td>45.0% *</td>
</tr>
<tr>
<td>minimal</td>
<td>3.7 %</td>
<td>18.2 %</td>
<td>-</td>
</tr>
<tr>
<td>selective</td>
<td>7.4 %</td>
<td>36.4 %</td>
<td>27.8 % ++</td>
</tr>
<tr>
<td>absolute</td>
<td>22.2 %</td>
<td>27.2 %</td>
<td>33.3 % *</td>
</tr>
<tr>
<td>subtotal</td>
<td>29.7 % ++</td>
<td>18.2 %</td>
<td>16.7 %</td>
</tr>
<tr>
<td>total</td>
<td>37.0 % ** , +</td>
<td>-</td>
<td>22.2 % **</td>
</tr>
<tr>
<td>Pronounced hyperacidity:</td>
<td>31.2 % *</td>
<td>20.6 %</td>
<td>30.0 %</td>
</tr>
<tr>
<td>minimal</td>
<td>-</td>
<td>42.8 %</td>
<td>-</td>
</tr>
<tr>
<td>selective</td>
<td>20.0 %</td>
<td>28.6 %</td>
<td>25.0 %</td>
</tr>
<tr>
<td>absolute</td>
<td>25.0 %</td>
<td>14.3 %</td>
<td>25.0 %</td>
</tr>
<tr>
<td>subtotal</td>
<td>30.0 % *</td>
<td>14.3 %</td>
<td>33.3 % *</td>
</tr>
<tr>
<td>total</td>
<td>25.0 % **</td>
<td>-</td>
<td>16.7 % *</td>
</tr>
</tbody>
</table>

Note: the difference between the indicators in patients of Group II and patients of Groups I and III is statistically significant: * - p <0,05; ** - p <0,01; the difference between the indicators in patients of Group I and Group III is statistically significant: ^ - p <0,05.
the values of gastric juice acidity on the digestive function of the alimentary tract in the diseased with several pathologies – chronic gastritis and with accompanying pancreas affection – has been investigated. The decrease of acid production of the stomach in the diseased I (chronic gastritis) and the diseased II (chronic gastritis with pancreas affection) has been detected, with more noticeable effect in the group with accompanying pathology [11]. Therefore, further study of gastric acid secretion, as well as the influence of DAN on its production against the background of autonomic disorders in patients with CP and type 2 diabetes has important diagnostic value in these patients for the selection of adequate treatment. Further research should also be conducted in this direction to reveal the relationship between DAN and digestive tract lesions, including CP in patients with type 2 diabetes.

CONCLUSIONS

1. Ewing, Shellong and 30:15 tests are effective methods for detecting DAN in patients with CP and type 2 diabetes.
2. The predominance of the parasympathetic division of the ANS, as well as manifestations of severe ANS dysfunction, are observed in patients with CP and type 2 diabetes.
3. The prevalence of gastric hyperacidity on the background of DAN was established in patients with CP and type 2 diabetes. In this case, the absence of clinical symptoms or their minimal severity is determined, which indicates the lesion of the digestive tract in these patients.

REFERENCES


Authors are responsible for the content and it does not necessarily represent the official views of the National Institutes. The scientific research was carried out within the scientific research work framework №851 “Mechanisms of the formation of complications in liver diseases and pancreas, methods of their treatment and prevention” (state registration number: 0115U001103), as well as the general department topic of the department of propaedeutics of internal diseases, as well as the scientific topic of the Department of Propaedeutics of Internal Medicine (Polymorbid pathology in diseases of the digestive system, features of pathogenesis, the possibility of correction (state registration number 0118U004365).

ORCID and contributionship:
Yelyzaveta S. Sirchak: 0000-0001-6738-0843 A,B,C,D
Vasiliy Ye. Barani: 0000-0002-2616-2230 C,D
Olena M. Odoshevskia: 0000-0003-3412-3554 E,F
Oksana I. Petrichko: 0000-0001-5420-6424 E

Conflict of interest:
The Authors declare no conflict of interest.

CORRESPONDING AUTHOR
Yelyzaveta S. Sirchak
Uzhhorod national university
3 Narodna sq., 88000 Uzhhorod, Ukraine
tel: +380309761794
e-mail: sirchakliza777@gmail.com

Received: 09.11.2020
Accepted: 02.03.2021

A – Work concept and design, B – Data collection and analysis, C – Responsibility for statistical analysis, D – Writing the article, E – Critical review, F – Final approval of the article